CancerNetwork Members: Login | Register
 
CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
PATIENTS
NURSES
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Bone Metastases

Oncology NEWS International. Vol. 19 No. 9
Cancer Care: Practice and Policy 

ASTRO guideline sets standard for use of radiotherapy as palliative treatment of pain from bone metastases

September 1, 2010
Stephen Lutz, MD, talks about the evolution of the ASTRO guideline and how it answers vital questions for radiation oncologists.

TABLE
ASTRO bone mets guideline
The guideline can be accessed at www.astro.org/Research/CommentForm/documents/BoneGLDraft.pdf. As of August 2010, ASTRO was deciding whether a session on the new guideline will be held at the ASTRO 2010 meeting in San Diego.

External-beam radiotherapy can rapidly relieve the pain of uncomplicated bone metastases, which makes EBRT one of the most commonly prescribed treatments. Its application, however, has been mired in debate over whether this palliative modality should be administered in single- or multiple-fraction regimens.

A new ASTRO guideline promises to end the handwringing by radiation oncologists who worry about choosing the right regimen. Scheduled for publication this fall in the International Journal of Radiation Oncology, Biology, Physics, the guideline concluded that single- and multiple-fraction regimens are so similar in clinical efficacy that the patient's circumstances and concerns should determine the choice (see Table).

STEPHEN LUTZ, MD
“Any more than one fraction, when someone is actively dying, is probably overdoing it.”
— STEPHEN LUTZ, MD

"Over the years there have been discussions about whether one-fraction or multiple-fraction [regimens] are optimal," said Stephen Lutz, MD, director of radiation oncology at Branchard Valley Regional Cancer Center in Findlay, Ohio. "With a couple caveats, [the guideline shows that] either one is reasonable."

Dr. Lutz handpicked and then led the committee of 17 experts in palliative radiotherapy that developed the guideline. This guideline will provide the basis for oncologists to feel comfortable offering either single- or multiple-fraction regimens to their patients.

"When you're talking about people, about their wishes, you can be surprised," he said. "Their choices can be widely variant."

Often the choice comes down to time, efficacy, and how each is perceived by the patient. Because many with metastatic bone disease have only a short time to live, multiple treatment regimens can absorb much of their remaining lives. By definition, single-fraction treatment is quick, relatively convenient, and cost-effective. The downside is that single-fraction therapy is associated with a 20% retreatment rate to the same site vs an 8% retreatment rate after a multiple-fraction regimen.

Multiple-fraction regimens, typically 10 doses totaling up to 30 Gy, have been incorrectly perceived to provide better long-term pain relief than the short course, often an 8 Gy single treatment. This misperception, when coupled with unfounded concerns about higher rates of pathologic fracture, spinal cord compression, and radiation myelitis after single fraction treatment, has limited the widespread use of single-fraction treatment. Complicating matters is the possibility that the patient may feel that "more is better" and that single-fraction treatment must therefore be inferior.

The ASTRO guideline deflates this patient concern, however, by putting the others in context. Research compiled by the committee indicates that the differences between single- and multiple-fraction regimens are minor.

Although a regimen of 30 Gy in 10 fractions has a lower incidence of retreatment of the same painful site, prospective randomized trials demonstrate that single-fraction EBRT provides equivalent pain control with similar or fewer side effects. If pain recurs, a single 8-Gy fraction can be safely and effectively repeated, according to the guideline. An added advantage of single-fraction treatment is its increased efficiency.

The guideline was completed in just eight months. In this time, the ASTRO committee examined data from 25 randomized trials, 20 prospective single-arm studies, and four meta-analyses/systematic reviews. The committee then gathered and incorporated the data into a final draft with comments from the oncology community and ASTRO board.

“The underlying comment was that it was imperative that [the bone pain guideline] make it clear that there are good choices, not just one choice.”
— STEPHEN LUTZ, MD

"The underlying comment we got was that it was imperative that [the guideline] make it clear there are good choices, not just one choice," Dr. Lutz said.

Stereotactic body radiotherapy was found to hold "theoretical" promise as a treatment for new or recurrent spine lesions, though the committee recommended that its use be limited to highly selected patients at centers familiar with the dosing and risks of SBRT and, preferably, on a prospective trial.

With regard to single- or multiple-fraction regimens, the choice depends on the patient and surrounding circumstances, according to Dr. Lutz. The more fractions, the less the chance pain will return and repeat treatments will be needed.

"But for someone who is really very sick and almost certainly approaching the end of life, they are probably much more willing to do a single fraction for the sake of convenience," he said. "Any more than one fraction, when someone is actively dying, is probably overdoing it."

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by bhavsar devang | December 19, 2010 12:10 PM EST

Dr. Lutz, thanks for your guideline, Astro guideline for palliative radiotherapy. Is any analysis on site wise like breast cancer or lung Or prostate?

by thanh ngocong | September 18, 2010 12:23 AM EDT

This is a  good guideline for me and my colleague. Thank to authors!






 
RELATED CONTENT

Evolution of Treatment Options for Patients With CRPC and Bone Metastases: Bone-Targeted Agents That Go Beyond Palliation of Symptoms to Improve Overall Survival
ONCOLOGY,  December 31, 2011
Are We Trumping Bone Disease in Prostate Cancer?
ONCOLOGY,  December 31, 2011
Managing CRPC: Improving Symptoms, Survival, or Both?
ONCOLOGY,  December 31, 2011
Cabozantinib Shows Promising Activity in Prostate Cancer Bone Metastases
August 24, 2011
ASCO 2011: Phase II Cabozantinib Trial in Patients with Advanced Solid Tumors and Bone Metastases
May 24, 2011
 
TOPIC INDEX

  • Bladder Cancer
  • Bone Metastases
  • Breast Cancer
  • CML
  • Colorectal Cancer
  • End-of-Life
  • GIST
  • Genetics Genomics
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Integrative Oncology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Nausea & Vomiting
  • Palliative Care
  • Pancreatic Cancer
  • Practice Management
  • Practice & Policy
  • Prostate Cancer
  • RCC
  • Skin Cancer
  • Triple-Negative Breast
  • Testicular Cancer


More Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
'What They Should Really Teach in Medical School'
Julie Schopps, MD , February 6, 2012
The North Carolina-based pediatrician weighs in on why she thinks the real learning doesn't take place until students are out of the classroom.
Improve EHR Systems by Rethinking Medical Billing
Daniel Essin, MA, MD, February 6, 2012
Separating billing-related data from other clinical documentation and transmitting it to a billing system is not difficult …no matter how the charting is done.
Keeping Your Medical Practice’s Accounts Receivable on Track
P.J. Cloud-Moulds, February 4, 2012
Here are the minimum reports you should be running to keep an eye on your practices A/R.
Healthcare Providers Play Crucial Role in Helping Victims of Abuse
Stephen Hanson, PA-C , February 3, 2012
I would urge each and every one of you to be familiar with the warning signs of abuse, and the resources available to you all as healthcare providers.
Protecting Your Medical Practice's Data
Marisa Torrieri, February 3, 2012
Here's the scoop on how to implement a good data-backup plan at your office.
 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Management of Brain Metastases: Neurosurgical Considerations
  • Optimizing Outcomes of Advanced Prostate Cancer: Drug Sequencing and Novel Therapeutic Approaches
  • Head and Neck Tumors
  • A 28-Year-Old Woman Presents With a Long-Standing History of Intermittently Painful “Bumps” on Both Her Shoulders and Upper Back
  • Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
  • Ending the Shortage of Generic Oncology Drugs
  • Processed and Red Meat Consumption Linked to Slight Increase in Risk of Pancreatic Cancer
  • Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
  • Younger Breast Cancer Patients Have More Adverse Quality of Life Issues
  • New Way to Predict Prostate Cancer Severity—Size of Prostate
  • AL Amyloidosis: Who, What, When, Why, and Where
  • The Maze of PARP Inhibitors in Ovarian Cancer
  • The Circuitous Path of PARP Inhibitor Development in Epithelial Ovarian Cancer
  • Podcast: Dr. David Ahlquist on Advances in Colorectal Cancer Screening
  • Lung Cancer Screening: A New Era
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • When to Treat Myelodysplastic Syndromes
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • PSA Screening for Prostate Cancer Put Into Question By the U.S. Preventive Services Task Force
  • PSA Screening for Prostate Cancer Put Into Question By the U.S. Preventive Services Task Force
  • When to Treat Myelodysplastic Syndromes
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • Are We Ready for Neoadjuvant Therapy in Potentially Resectable Pancreatic Cancer?
  • Evolving Therapeutic Paradigms for Advanced Prostate Cancer
Click here to subscribe to our newsletter
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Bone Metastases
Evidence on Bone Metastases
Guidelines on Bone Metastases
Patient Education on Bone Metastases
Clinical Trials on Bone Metastases
Practical Articles on Bone Metastases
Research and Reviews on Bone Metastases
All "Bone Metastases" results


CancerNetwork on Facebook

 

CancerNetwork | CME LLC | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2012 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy